Bavdegalutamide

Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer (Pink: AR ligand (HY-168299) ; Blue: E3 ligase ligand (HY-W093272) ; Black: linker (HY-W091986) ) [1].

Product Specifications

CAS Number

[2222112-77-6]

Product Name Alternative

ARV-110

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Androgen Receptor; PROTACs

Type

Reference compound

Related Pathways

PROTAC; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/arv-110.html

Purity

99.64

Solubility

DMSO : 26.67 mg/mL (ultrasonic; warming; adjust pH to 3 with HCl; heat to 80°C)

Smiles

O=C(C1=NN=C(N2CCC(CN3CCN(C4=CC5=C(C(N(C(CC6)C(NC6=O)=O)C5=O)=O)C=C4F)CC3)CC2)C=C1)N[C@H]7CC[C@H](OC8=CC=C(C#N)C(Cl)=C8)CC7

Molecular Formula

C41H43ClFN9O6

Molecular Weight

812.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Taavi Neklesa, et al. ARV-110: An androgen receptor PROTAC degrader for prostate cancer. American Association for Cancer Research. 2018. 78 (13) : pp. 5236.|[2]Taavi K Neklesa, et al. ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer. GU ASCO 2019